ArticleFrontiers in endocrinology2026
Diagnostic value of 24-h urinary aldosterone and related biomarkers for screening primary aldosteronism in medication-exposed populations.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the screening value of 24-hour urinary aldosterone (24h-Uald) and the urinary aldosterone-to-renin ratio (UARR) for primary aldosteronism (PA in hypertensive patients under conditions of ongoing antihypertensive medication use. Methods: Hypertensive patients who underwent PA screening at our hospital between August 2024 and August 2025 were retrospectively enrolled. Baseline clinical characteristics and biochemical parameters were collected while patients were receiving ongoing antihypertensive therapy. Multivariable logistic regression analysis was performed to assess the independent associations of 24h-Uald and UARR with PA. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis. Results: Both 24h-Uald and UARR levels were significantly higher in patients with PA than in those with essential hypertension (EH) (P < 0.05). After adjustment for potential confounders, including age, body mass index, renal function, and history of coronary artery disease, 24h-Uald and UARR remained independently associated with PA. ROC curve analysis demonstrated a modest diagnostic performance for 24h-Uald (AUC = 0.657), whereas UARR exhibited excellent diagnostic accuracy (AUC = 0.862). Conclusions: Under conditions of ongoing antihypertensive medication use, the diagnostic performance of 24h-Uald alone for PA screening is limited. In contrast, UARR, incorporating renin measurements, demonstrates higher diagnostic accuracy and greater clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.